---
title: "Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244689160.md"
description: "Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data Expected in Second Half of 2026"
datetime: "2025-06-16T11:03:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244689160.md)
  - [en](https://longbridge.com/en/news/244689160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244689160.md)
---

# Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data Expected in Second Half of 2026

### Related Stocks

- [GLYC.US](https://longbridge.com/en/quote/GLYC.US.md)
- [CRGY.US](https://longbridge.com/en/quote/CRGY.US.md)